Four details:
1. The agreements to commercialize CytoSorb will “aggressively” expand product availability, marketing and sales operations in Florida, as well as in the Northeast and Mid-Atlantic regions.
2. CytoSorb is designed to treat cytokine release syndrome, a condition that could otherwise cause serious inflammation, organ failure and death in patients with common critical conditions.
3. The FDA granted emergency use authorization of CytoSorb in April, allowing the product to be used in adult, critically ill COVID-19 patients with imminent or confirmed respiratory failure.
4. Surgical Partners is a sales and marketing distribution partner for medical device manufacturers, and InvoSurg is a medical device distribution company with experience in cardiac surgery and extracorporeal life support. Financial terms of their agreements with CytoSorbents weren’t disclosed.
More articles on surgery centers:
3 ASC developments worth over $10M
7 critical steps for financial success in your ASC
10 most common procedures in ASCs
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.